PubMed · 17107286
Prasugrel.
Abstract
Clinical trials have demonstrated the superior clinical efficacy of dual antiplatelet therapy with a thienopyridine (a P2Y(12) receptor blocker) and aspirin (COX-1 inhibitor) in patients undergoing stenting as well as patients with acute coronary syndromes. However, clopidogrel treatment is associated with a wide response variability and non-responsiveness in selected patients. The latter phenomenon is linked to the occurrence of recurrent ischaemic events including stent thrombosis in the recent studies. Prasugrel is a new thienopyridine derivative that produces more potent platelet inhibition and a rapid onset of action that is associated with irreversible P2Y(12) receptor blockade. The latter properties of prasugrel may provide a superior alternative to clopidogrel, with less response variability and a decreased prevalence of non-responsiveness.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Udaya S Tantry, Kevin P Bliden, Paul A Gurbel. 2006. Prasugrel.. https://doi.org/10.1517/13543784.15.12.1627
Cite the original work for its findings. Save a collection to share your selection of sources.